The chemoresistance of human malignant melanoma: An update

Melanoma Research

Volumn 9, Issue 1, 1999, Pages 51-58

  Serrone, L ^a   Hersey, P ^b  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Chemoresistance; Chemotherapy induced apoptosis; Melanoma; Review

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOTEMUSTINE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; MELPHALAN; MULTIDRUG RESISTANCE PROTEIN; VINBLASTINE; VINDESINE;

APOPTOSIS; ARTICLE; HUMAN; MELANOMA; MULTIDRUG RESISTANCE; ONCOGENE RAS; PRIORITY JOURNAL;

EID: 0032944017     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199902000-00007     Document Type: Article

References (67)

1. 1. Guerry DP, Schuchter LM. Disseminated melanoma is there a new standard therapy? N Engl J Med 1992; 327: 560-561.
2. 2. Schadendorf D, Worm M, Algermissen B, Kohlmus CM, Czarnetzki BM. Chemosensitivity testing of human melanoma cells: retrospective analysis of clinical response and in vitro drug sensitivity. Cancer 1994; 73: 103-108.
3. 3. Kartner N, Everden-Portelle D, Bradley G, Ling V. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 1986; 316: 820-823.
4. 4. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 1989; 58: 137-171.
5. 5. Fuchs B, Ostmeier H, Suter L. P-glycoprotein expression in malignant melanoma. J Cancer Res Clin Oncol 1991; 117: 168-171.
6. 6. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai S-L, Gardar A, Pirker R, Green A, Crist W, Brodeur GM, Lieber M, Cossman J, Gottesman MM, Pastan I. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989; 81: 116-124.
7. 7. Levine EA, Holzmayer TA, Roninson IB, Gupta TKD. MDR-1 expression in metastatic malignant melanoma. J Surg Res 1993; 54: 621-624.
8. 8. Ramachandran C, Yuan ZK, Huang XL, Krishan A. Doxorubicin resistance in human melanoma cells: MDR-1 and glutathione S-transferase π gene expression. Biochem Pharmacol 1993; 45: 743-751.
9. 9. Ramachandran C, Samy TS, Huang XL, Yuan ZK, Krishan A. Doxorubicin-induced DNA breaks, topoisomerase Π activity and gene expression in human melanoma cells. Biochem Pharmacol 1993; 45: 1367-1371.
10. 10. Berger W, Elbling L, Minai-Pour M, Vetterlein M, Pirker R, Kokoschka EM, Micksche M. Intrinsic MDR-1 and P-glycoprotein expression in human malignant melanoma. Int J Cancer 1994; 59: 717-723.
11. 11. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650-1654.
12. 12. Loe DW, Deeley RG, Cole SP. Biology of the multidrug resistance-associated protein, MRP. Eur J Cancer 1996; 32A: 945-957.
13. 13. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC, Deeley RG. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 1994; 54: 357-361.
14. 14. Cole SPC, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM, Deeley RG. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 1994; 54: 5902-5910.
15. 15. Schadendorf D, Makki A, Stahr C, van Dyck A, Wanner R, Scheffer GL, Flens MJ, Scheper R, Henz BM. Membrane transport proteins associated with drug resistance expressed in human melanoma. Am J Pathol 1995; 147: 1545-1552.
16. 16. Berger W, Hauptmann E, Elbling L, Vetterlein M, Kokoschka EM, Micksche M. Possible role of the multidrug resistance-associated protein (MRP) in chemoresistance of human melanoma cells. Int J Cancer 1997; 71: 108-115.
17. 17. Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE, Cowan KH. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 1986; 261: 15544-15549.
18. 18. O'Brien ML, Tew KD. Glutathione and related enzymes in multidrug resistance. Eur J Cancer 1996; 32A: 967-978.
19. 19. Colvin OM, Friedman HS, Gamcsik MP, Fenselau C, Hilton J. Role of glutathione in cellular resistance to alkylating agents. Adv Enzyme Regulation 1993; 33: 19-26.
20. 20. Hamilton TC, Winker MA, Louie KG, Batist G, Behrens BC, Tsuruo T, Grotzinger KR, Mc Koy WM, Young RC, Ozols RF. Augmentation of adriamycin, melphalan and cisplatin cytotoxicity in drug-resistant and sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol 1985; 34: 2583-2586.
21. 21. Chao CCK, Huang YJ, Ma CM, Chou W-Y, Lin-Chao S. Overexpression of glutathione S-transferase and elevation in thiol pools in a multidrug-resistant human colon cancer cell line. Mol Pharm 1992; 41: 69-75.
22. 22. Natali PG, Nicotra MR, Citro G, Cucco C, Bigotti A, Kantor RR. Expression of glutathione transferase π in benign and malignant lesions of the melanocyte lineage. Melanoma Res 1992; 2: 219-223.
23. 23. Schadendorf D, Czarnetzki BM. Drug resistance of malignant melanoma. Mechanisms and possible modulation. Hautarzt 1994; 45: 678-684.
24. 24. Benathan M, Alvero-Jackson H, Mooy AM, Scaletta C, Frenk E. Relationship between melanogenesis, glutathione levels and melphalan toxicity in human melanoma cells. Melanoma Res 1992; 2: 305-314.
25. 25. Wang YY, Teicher BA, Shea TC, Holden SA, Rosbe KW, al-Achi A, Henner WD. Cross-resistance and glutathione S-transferase π levels among four human melanoma cell lines selected for alkylating agent resistance. Cancer Res 1989; 49: 6185-6192.
26. 26. Schadendorf D, Jurgovsky K, Kohlmus CM, Czarnetzki BM. Glutathione and related enzymes in tumor progression and metastases of human melanoma. J Invest Dermatol 1995; 105: 109-112.
27. 27. Holm C, Goto T, Wang JC, Botstein D. DNA topoisomerase II is required at the time of mitosis in yeast. Cell 1985; 41: 553-563.
28. 28. Wang JC, Caron PR, Kim RA. The role of DNA topoisomerases in recombination and genome stability: a double-edged sword? Cell 1990; 62: 403-406.
29. 29. Tan KB, Dorman TE, Falls KM, Chung TD, Mirabelli CK, Crooke ST, Mao J. Topoisomerase IIα and topoisomerase IIβ genes: characterization and mapping to human chromosomes 17 and 3, respectively. Cancer Res 1992; 52: 231-234.
30. 30. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989; 58: 351-375.
31. 31. Webb CD, Latham MD, Lock RB, Sullivan DM. Attenuated topoisomerase II content directly correlates with low levels of drug resistance in a chinese hamster ovary cell line. Cancer Res 1991; 51: 6543-6549.
32. 32. Cole SP, Chanda ER, Dicke FP, Gerlach JH, Mirski SEL. Non P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cancer Res 1991; 51: 3315-3352.
33. 33. Campain JA, Gottesman MM, Pastan I. A novel mutant topoisomerase IIα present in VP-16 resistant human melanoma cell lines has a deletion of alanine 429. Biochemistry 1994; 33: 11327-11332.
34. 34. Bos JL. Ras oncogenes in human cancer: a review, Cancer Res 1989; 49: 4682-4689.
35. 35. Barbacid M. Ras genes. Annu Rev Biochem 1989; 56: 779-827.
36. 36. van't Veer LJ, Burgering BMT, Versteeg R, Boot AJM, Ruiter DJ, Osanto S, Schrier PI, Bos JL. N-Ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol 1989; 9: 3114-3116.
37. 37. Albino AP, Fountain JW. Molecular genetics of human malignant melanoma. In: Nathanson L, ed. Current Research and Clinical Management of Melanoma. Dordrecht: Kluwer, 1993: 201-255.
38. 38. Ball NJ, Yohn JJ, Morelli JG, Norris DA, Golitz LE, Hoeffler JP. Ras mutations in human melanoma: a marker of malignant progression. J Invest Dermatol 1994; 102: 285-290.
39. 39. Shukla VK, Hughes DC, Hughes LE, McCormick F, Padua RA. Ras mutations in human melanocytic lesions: K-Ras activations, a frequent and early event in melanoma development. Oncogene Res 1989; 5: 121-127.
40. 40. Jansen B, Inoue SA, Wadl H, Eichler HG, Wolff K, Van Elsas A, Schrier PI, Pehamberger H. N-Ras oncogene expression changes the growth characteristics of human melanoma in two independent SCID-Hu mouse models. Int J Cancer 1996; 67: 821-825.
41. 41. Jansen B, Schlagbauer-Wadl H, Eichler H-G, Wolff K, van Elsas A, Schrier PI, Pehamberger H. Activated N-ras contributes to the chemoresistance of human melanoma in severe combined immunodeficiency (SCID) mice by blocking apoptosis. Cancer Res 1997; 57: 362-365.
42. 42. Nooter K, Boersma AWM, Oostrum RG, Burger H, Jochemsen AG, Stoter G. Constitutive expression of the c-H-ras oncogene inhibits doxorubicin-induced apoptosis and promotes cell survival in a rhabdomyosarcoma cell line. Br J Cancer 1995; 71: 556-561.
43. 43. Peters GJ, Wets M, Keepers YP, Oskam R, van Ark-Otte J, Noordhuis P, Smid K, Pinedo HM. Transformation of mouse fibroblasts with the oncogenes H-Ras or trk is associated with pronounced changes in drug sensitivity and metabolism. Int J Cancer 1993; 54: 450-455.
44. 44. Wani MA, Xu X, Stambrook PJ. Increased methotrexate resistance and dhfr gene amplification as a consequence of induced Ha-ras expression in NIH 3T3 cells. Cancer Res 1994; 54: 2504-2508.
45. 45. Schimke RT. Gene amplification in cultured animal cells. Cell 1984; 37: 705-713.
46. 46. Cillo C, Dick JE, Ling V, Hill RP. Generation of drug-resistant variants in metastatic B16 mouse melanoma cell lines. Cancer Res 1987; 47: 2604-2608.
47. 47. Kinoshita T, Yokota T, Arai K, Miyajima A. Regulation of Bcl-2 expression by oncogenic Ras protein in hematopoietic cells. Oncogene 1995; 10: 2207-2212.
48. 48. Tsujimoto Y, Yunis J, Onorato-Showe L, Erkson J, Nowel PC, Croce CM. Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(14:18) chromosome translocation. Science 1984; 224: 1403-1406.
49. 49. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994; 124: 1-6.
50. 50. Plettenberg A, Ballaun C, Pammer J, Mildner M, Strunk D, Weninger W, Tschachler E. Human melanocytes and melanoma cells constitutively express the Bcl-2 protooncogene in situ and in cell culture. Am J Pathol 1995; 146: 651-659.
51. 51. van den Oord JJ, Vandeghinste N, De Ley M, De Wolf-Peeters C. Bcl-2 expression in human melanocytes and melanocytic tumors. Am J Pathol 1994; 145: 294-300.
52. 52. Jay V, Yi Q, Hunter WS, Zielenska M. Expression of bcl-2 in uveal malignant melanoma. Arch Pathol Lab Med 1996; 120: 497-498.
53. 53. Tron VA, Krajewski S, Klein-Parker H, Li G, Ho VC, Reed JC. Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma. Am J Pathol 1995; 146: 643-650.
54. 54. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy induced apoptosis in a human leukemia cell line. Blood 1993; 81: 151-157.
55. 55. Keith FJ, Bradbury DA, Zhu Y-M, Russell NH. Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Leukemia 1995; 9: 131-137.
56. 56. Xie K, Wang Y, Huang S, Xu L, Bielenberg D, Salas T, McConkey DJ, Jiang W, Fidler IJ. Nitric oxide-mediated apoptosis of k-1735 melanoma cells is associated with downregulation of Bcl-2. Oncogene 1997; 15: 771-779.
57. 57. Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, van Elsas A, Muller M, Wolff K, Eichler H-G, Pehamberger H. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nature Med 1998; 4: 232-234.
58. 58. Albino AP, Widal MJ, McNutt NS, Shea CR Prieto VG, Nanus DM, Palmer JM, Hayward NK. Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res 1994; 4: 35-45.
59. 59. Sparrow LE, Soong R, Dawkins HJ, Iacopetta BJ, Heenan PJ. p53 gene mutation and expression in naevi and melanomas. Melanoma Res 1995; 5: 93-100.
60. 60. Hartmann A, Blaszyk H, Cunnigham JS, McGovern RM, Schroeder JS, Helander SD, Pittelkow MR, Sommer SS, Kovach JS. Overexpression and mutations of p53 in metastatic melanoma. Int J Cancer 1996; 67: 313-317.
61. 61. Fan S, el-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace AJ Jr, Magrath I, Kohn KW, O'Connor PM. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 1994; 54: 5824-5830.
62. 62. Righetti SC, Torre GD, Pilotti S, Menard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, Bohm S, Bresciani GL, Spatti G, Zunino F. A comparative study of p53 gene mutation, protein accumulation and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996; 56: 689-693.
63. 63. Nabeya Y, Loganzo F Jr, Maslak P, Lai L, de Oliveira AR, Schwartz GK, Blundell ML, Altorki NK, Kelsen DP, Albino AP. The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int J Cancer 1995; 64: 37-46.
64. 64. Lowe SW, Ruley HE, Jacks T, Housman DE. p53 dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-967.
65. 65. Li G, Tang L, Zhou X, Tron V, Ho V. Chemotherapy-induced apoptosis in melanoma cells is p53 dependent. Melanoma Res 1998; 8: 17-23.
66. 66. Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 1992; 11: 121-139.
67. 67. Barry MA, Behnke CA, Eastman A. Activation of programmed cell death by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 1990; 40: 2353-2362.